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he purpose of  this study is to investigate the feasibility and safety of  colorectal 
surgery plus adjuvant intraoperative hyperthermic intraperitoneal chemotherapy in 
patients at high risk of  peritoneal recurrence, but still without pre- or intra-
operative evidence of  peritoneal spread in terms of  length of  hospital stay, surgical and medical 























im: prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) showed 
promising results in patients with colorectal carcinoma at high risk of  recurrence, 
but still without clinically and radiologically evident signs of  peritoneal spread. 
This study aims to analyze the feasibility of  this proactive, early phase, multimodality approach.  
Methods: a mono-institutional, prospective, parallel, two-stage phase II trial enrolled 49 patients to 
standard surgery or surgery plus intraoperative HIPEC. Before the procedure and during surgery 
patients received intravenous fluorouracil and leucovorin to potentiate oxaliplatin activity. Data 
analysis included length of  hospital stay, surgery duration, type of  surgery and chemotherapy-
related complications risk score.  
Results: no significant difference was seen in the median time spent in the hospital with a median 
stay of  7 days in both groups (p=0.5720). The surgical procedure median duration was longer in 
the HIPEC group than in the control one. Side-effects and surgical complications did not cross 
at any time the Pocock-type boundary for side/effect monitoring (p=0.80, N.S.).  
Conclusions: the present prospective study results demonstrate the feasibility and safety of  the 
colorectal surgery plus HIPEC treatment in patients with colorectal cancer patients at high-risk 















1.1. Colo-rectal cancer 
lobally, colorectal cancer (CRC) is the third most common cancer in males and the 
second in females, with 1.8 million new cases and almost 861,000 deaths in 20181. Its 
incidence and mortality rates vary markedly around the world1. 
Once a CRC is suspected the pretreatment clinical staging permits to classify it according the 
tumor, node, metastasis (TNM) staging system of  the combined American Joint Committee on 
Cancer (AJCC)/Union for International Cancer Control (UICC) (eighth edition, 2017)2. 
Surgical resection is the only curative modality for localized colon cancer. The goal of  surgery for 
invasive cancer is complete removal of  the tumor, the major vascular pedicle and the lymphatic 
drainage basin of  the affected colonic segment3. En bloc resection of  contiguous structures is 
indicated if  attachment or infiltration of  the tumor into a potentially resectable organ or 
structure is present. 
Approximately 20 to 25% of  newly diagnosed colon cancers are metastatic at presentation 
(synchronous metastasis). The most common distant metastatic sites are the liver, the lungs, the 
lymph nodes and the peritoneum.  
Although major advances in systemic chemotherapy have expanded the therapeutic options for 
these patients and improved median survival from less than one year in the single-agent 
fluoropyrimidine era to more than 30 months, fewer than 20%4 of  those treated with 
chemotherapy alone are still alive at five years and only a few are free of  disease, unless resection 
or ablation of  metastases has been performed. 
On the other hand, surgery provides a potentially curative option for selected patients with 
limited metastatic disease, predominantly in the liver and the lung.  






Peritoneal carcinosis is a metastatic deposit on the peritoneal surface throughout the abdominal 
cavity. The peritoneum is the second most common site of  metastasis in patients with colorectal 
cancer, accounting for 25–35% of  all cases of  recurrence6,7.  Among patients with recurrent 
disease, 5–10% have synchronous disease and 20–50% develop metachronous peritoneal 
carcinosis (PC)8-11. 
1.2. Pathophysiology of  colorectal peritoneal carcinosis 
Understanding the mechanism of  peritoneal dissemination from the primary tumor plays a key 
role in the prevention and early detection of  PC from CRC. Systemic tumor dissemination is 
considered to be a multistep process in which tumor cells detach from the primary tumor, acquire 
motility and evade anoikis (figure 1). In both hematogenous and peritoneal spread, free cancer 
cells (carried by the blood stream or floating in the peritoneal cavity) must evade immune 
defenses in order to reach host organs. At the site of  the host organ, adhesive interactions 
between the organ and cancer cells are required for the development of  metastasis12. Specific 
local environmental factors indicate that peritoneal and hematogenous spread only partially share 
target adhesion molecules and dissemination processes13. Detachment of  cancer cells into the 
free peritoneal space can occur as a result of  full thickness invasion through the serosa (T4 stage) 
or as a consequence of  surgery-induced tumor spillage. Once a viable, free cancer cell is present 
in the peritoneal cavity, adhesion to the peritoneal surface is required in order to ultimately invade 
the peritoneum, proliferate and produce peritoneal deposits12. Upregulation of  specific cell 
surface molecules due to the production of  reactive oxygen species and inflammatory cytokines 
may partially explain higher cancer cell adhesion during the postoperative period14. Considering 
tumor cell adhesion as a key step in the formation of  peritoneal deposits, a large literature review 
has investigated the functional importance of  various adhesion molecules and their correlation 
with clinical outcomes.  Currently, only a minority of  these targets (CD44, integrin α2β1 and 
mucin 16 [MUC16]) are supported by scientific data corroborating their implication in peritoneal 
dissemination in digestive and ovarian cancers. Experimental studies focused on the role of  
CD44, a cell surface proteoglycan participating in cell–cell interaction, adhesion and migration 
have underscored the potential role of  this protein in the development of  PC in gastric, ovarian 
and pancreatic carcinoma. Other in vivo experiments blocking interaction with mesothelial cells 
or increasing the delivery of  chemotherapy to malignant cells by specific agents show promise for 
inhibiting peritoneal dissemination. In addition, blocking integrin α2β1 results in poorer cancer 




adhesion of  CRC cells to the peritoneum. For this purpose, other compounds that diminish 
integrin β1-chain expression, such as phospholipids, endostatin and simvastatin, might also be 
effective and warrant further investigation. Likewise, MUC16 is probably implicated in 
mesothelial cell adhesion, as suggested by experimental studies in ovarian cancer and by a high 
level of  MUC16 in the serum of  patients with gastric cancer. Consequently, a better 
understanding of  these interactions and of  the mechanisms of  peritoneal dissemination could 
help prevent PC and facilitate the diagnosis of  patients at risk of  developing PC in the future. 
1.3. Treatment options: cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy. Rationale 
Peritoneal carcinosis has historically been regarded as an untreatable disease and, despite 
advances, has remained a significant challenge for oncologists and surgeons. For many years, 
patients with PC have been considered to be beyond the realm of  curative therapy, but in recent 
years promising results have been reported in a variety of  tumor types using cytoreductive 
surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). 
CRS-HIPEC is a complex therapeutic modality. It includes an aggressive and extensive surgical 
procedure and the administration of  intraperitoneal chemotherapy with hyperthermia, either in 
the intraoperative or/and in the early postoperative setting. 
In expert hands, the associated morbidity and mortality compares that of  other major oncological 
surgery15, but this expertise needs to be gained. Awareness of  treatment-related toxicity is 
important and needs to be factored in the patient selection process. 
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is delivered in the operating room once 
the cytoreductive surgical procedure is finalized and constitutes the most common form of  
administration of  perioperative intraperitoneal chemotherapy. The acronym HIPEC, coined by 
the group from the Netherlands Cancer Institute, has become the standardized nomenclature for 
this procedure as a result of  the experts’ consensus achieved during the Fourth International 
Workshop on Peritoneal Surface Malignancy (Madrid, 2004)16.  
Intraperitoneal delivery of  anti-neoplastic agents for cancer into the abdominal cavity has been 
attempted since antiquity. In the mid-18th century, English surgeon Christopher Warrik injected a 
mixture of  “Bristol water” and “Claret” (a Bordeaux wine) into the peritoneal cavity of  a woman 
suffering from intractable ascites17. The efficacy of  this novel method for intraperitoneal drug 
delivery for peritoneal metastases patients has been slowly developed. Karnofsky and colleagues 




was such that FDA approval of  nitrogen mustard for intraperitoneal administration was granted 
and has remained in effect until now18. However, the rationale for intraperitoneal chemotherapy 
administration came from pharmacologic research in patients who had cancer spread to 
peritoneal surfaces. It was recognized that some drugs would be especially appropriate for 
prolonged retention within the peritoneal space based on their molecular structure19. It was 
Dedrick and colleagues at the American National Institutes of  Health who called attention to the 
potential benefits of  intraperitoneal chemotherapy administration of  cancer chemotherapy agents 
especially in ovarian cancer20. The studies of  Speyer and colleagues clearly identified 5-
fluorouracil as an agent with high concentrations within the peritoneal space after intraperitoneal 
administration as compared to drug levels within the plasma21. The rapid metabolism of  the 5-
fluorouracil after absorption of  this drug by the visceral peritoneum within the liver parenchyma 
resulted in a markedly enhanced exposure of  cancer nodules on peritoneal surfaces22. Jones and 
colleagues recognized that a high volume of  intraperitoneal chemotherapy solution (belly bath 
technique) was necessary to adequately distribute the drugs23. Ozols and colleagues investigated 
the pharmacokinetics of  doxorubicin and McVee and colleagues the possible benefits of  
intraperitoneal cisplatin24-25. Thanks to the continuous efforts to identify suitable drugs for the 
administration of  intraperitoneal chemotherapy, an extensive list of  possible chemotherapeutic 
agents and their pharmacologic advantages after intraperitoneal administration has been 
defined26. 
Because of  a large molecular size and hydrophobic surface, cancer chemotherapy agents were 
shown to have a slow clearance from the peritoneal compartment through the lining of  the 
abdomen and pelvis to the body compartment. Moreover, metabolism of  the chemotherapy in 
the body compartment was at all points in time faster than clearance from the peritoneal space. 
This resulted in a much greater concentration times- time (area under the curve) of  the drug in 
the peritoneal space as compared to concentration times- time measured in the blood. This 
results in an increased therapeutic effect on cancer nodules on the peritoneal surface and a 
reduced systemic toxicity27. 
The combination of  heat and cytotoxic drugs frequently results in an increased cytotoxicity, 
beyond that predicted for an additive effect. The synergism between both kinds of  treatment is 
dependent on several factors including increased drug uptake in malignant cells which is due to 
increased membrane permeability and improved membrane transport. There is also evidence that 
heat may alter cellular metabolism and change drug pharmacokinetics and excretion, both of  




include increased drug penetration in tissue, temperature dependent increases in drug action and 
inhibition of  repair mechanisms. In many cases, this enhancement of  activity and penetration 
depth of  drugs has already been seen above 39-40°C28. 
1.4. Prevention of  peritoneal metastases with intra-operative proactive 
HIPEC treatment after conventional colon-rectal cancer surgery 
Recent improvements in the surgical technology of  colorectal cancer resection have decreased 
the incidence of  treatment failures, both at the resection site or at a distance from the primary. 
The benefits of  total mesorectal excision have been established and the survival benefit 
published29, 30. This survival advantage has been a result of  the absence of  tumor contamination 
within the confines of  the pelvis because of  a meticulous dissection which maintains a layer of  
tissue between the primary malignancy and the margins of  resection30. Also, the benefits of  colon 
cancer resection using wide excision, generous lymphadenectomy and an intact mesocolic 
resection have been demonstrated. These improvements in surgical technology and therefore in 
survival are the result of  decreased tumor cell contamination resulting from the surgical event 
itself. A complete absence of  tumor cell contamination with primary colorectal cancer surgery 
has become an absolute requirement of  treatment. Any dependence upon systemic 
chemotherapy to manage resection site disease or peritoneal metastases must be abandoned. 
It is important to establish that the mechanism of  resection site recurrence and peritoneal 
metastases is the same. Cancer cells are disseminated either prior to or at the time of  the cancer 
resection. The cancer cells at high density will layer out within the bed of  the resection site. 
Because the surgery has disrupted the peritoneum and created a “sticky surface”, a high 
metastatic efficiency is expected. Single cells disseminated at a distance from the anatomic site of  
primary cancer resection will progress as peritoneal metastases31. 
One of  the most innovative concepts in colorectal cancer in recent years has been that of  
“patients at high risk of  recurrence” and its identification. In approximately 20% of  patients with 
primary colorectal cancer, some clinical findings indicate a high probability of  intraperitoneal 
cancer cell dissemination32. These clinical findings show that the primary colorectal cancer 
surgery, even performed in its most perfect manner with or without systemic chemotherapy, is 
not a sufficient management strategy.  
Honoré et al33 defined patients at risk of  developing PC: small peritoneal nodules present in the 
first surgery (70%), ovarian metastases (60%) and perforated tumor (50%). Positive cytology and 




colorectal cancer really worsens the prognosis according to the Lyon’s series review with median 
overall survival (OS) of  19 and 44 months for positive and negative intraperitoneal free cancer 
cells (p .0.018).A recent review on advanced primary tumors (T4) confirms that T4a tumors are 
worse than T4b as a prognostic factor for peritoneal metastases development after 
primaryresection34. Sugarbaker35 defined the risk of  peritoneal recurrence according to some 
clinical and histopathological characteristics of  the tumor (Table 1).The identification of  these 
groups allowed Segelman et al.to develop an individualized prediction model to estimate each 
patient’s risk36, 37. In groups 1–4, patients can be considered to have 50–100% incidence of  local–
regional recurrence and/or peritoneal metastases in the absence of  special treatments. Peritoneal 
metastases discovered and resected at the time of  primary colorectal cancer resection will show 
progression with follow-up in 75% of  patients. This occurs even if  these metastases are 
completely removed with the primary intervention33. Ovarian metastases have over 60% 
incidence of  other sites of  peritoneal dissemination in follow-up. Perforation through the 
primary cancer at the time of  primary cancer resection and a positive margin of  resection, usually 
a lateral margin, indicates a likelihood of  local–regional or peritoneal progression in 30 and near 
100% of  patients, respectively. 
Other clinical findings have been shown to place the patient at a lesser risk for local–regional 
recurrence or peritoneal metastases. Positive peritoneal cytology either before or after colorectal 
cancer resection, adjacent organ involvement or a cancer-induced fistula, T3 mucinous cancers, 
T4 cancers or a positive imprint cytology from the primary malignancy, rupture of  the cancerous 
mass, or obstruction at the time of  presentation all would have an elevated incidence of  local–
regional recurrence and peritoneal metastases. 
The development of  metachronous PC was associated independently with non-R0 surgery (p < 
0.001), pN2 with lymphadenectomy with less than 12 nodes (p < 0.001), pT4 (p < 0.001), tumors 
located in the right colon (p < 0.002) and emergency surgery (p <0.001). It was possible estimate 
the risk for each patient. It was very important to identify these patients because they have poor 
survival rates at 5 years and new strategies are being developed to improve their prognosis38. 
1.5. Data Showing Benefit from Perioperative Chemotherapy in Patients 
with Primary Colorectal Cancer with Peritoneal Seeding or at High 
Risk for Peritoneal Seeding 
Local–regional recurrence and peritoneal metastases occupy a prominent role in the natural 




surgical intervention to control local–regional recurrence and peritoneal dissemination from 
colorectal cancer was proposed by Sugarbaker and colleagues39-41. In a phase I/II study, 5- 
fluorouracil and mitomycin C were administered directly into the peritoneal cavities in the early 
postoperative period before adhesions had progressed. There was a marked pharmacokinetic 
advantage of  perioperative intraperitoneal chemotherapy with single cancer cells on peritoneal 
surfaces as the targets of  this treatment. 
Experience with patients demonstrating peritoneal metastases recognized at the time of  primary 
colon cancer resection came from Washington and was reported by Pestieau and Sugarbaker42. 
They identified five patients who had definitive treatment of  peritoneal metastases from colon 
cancer concomitant with the resection of  the primary tumor. At the time of  writing their paper, 
the median disease-free survival of  these patients had not been reached and their 5-year survival 
was 100%. The statistical difference between patients who had perioperative treatment of  their 
peritoneal metastases as compared to those who had delayed management with cytoreductive 
surgery and early postoperative intraperitoneal chemotherapy (EPIC) was statistically significant 
(p < 0.0001). 
Tentes et al. has reported their experience on the use of  hyperthermic perioperative 
chemotherapy in patients at high risk for local–regional recurrence. Those were patients with 
locally advanced T3 or T4 colorectal cancer. Only patients with R-0 resection were randomly 
assigned to receive HIPEC plus systemic chemotherapy versus conventional treatments. The 5- 
year survival for the HIPEC group was 100% and 72% for the conventional group (p = 0.0938). 
During follow-up, two patients in the HIPEC group and eight patients in the conventional group 
were recorded with recurrence (p = 0.002). It is important to note that no local–regional 
recurrence or peritoneal metastases was recorded in the HIPEC group. By contrast, the group 
treated in a conventional manner showed three patients with local–regional recurrence. These 
data suggest that perioperative chemotherapy had no effect on the development of  distant 
metastases but exhibited an advantage in eradicating viable cancer cells that were disseminated 
local–regionally at the time or prior to the colorectal cancer resection43. 
Braam and colleagues reported a total of  72 patients with synchronous peritoneal metastases 
from colorectal cancer. In 20 patients (27.8%), the primary tumor was resected simultaneously 
with HIPEC (early referral). In the other 52 patients (72.2%), the primary tumor was resected 
prior to a reoperative surgery with HIPEC (late referral). During CRS plus HIPEC following late 
referral, 22 (59.5%) of  the 37 anastomoses of  the earlier operation were resected, revealing 




was constructed after HIPEC. The relaparotomy rate was higher in patients after a resection of  a 
previous anastomosis (36.4%) compared to 12% in the rest of  the patients (p = 0.02). Resection 
of  the primary tumor simultaneously with HIPEC in patients with synchronous peritoneal 
metastases from colorectal cancer may prevent extended bowel resections and permanent 
colostomy44. 
To date, the optimal perioperative chemotherapy treatment for prevention of  local–regional 
recurrence and peritoneal metastases has not been determined. It is possible that the best choice 
is the early postoperative intraperitoneal chemotherapy (EPIC). 
This was used by Pestieau and Sugarbaker to achieve good results42. Also, in the prevention of  
peritoneal metastases in gastric cancer, EPIC was shown by Yu et al. to be very successful in a 
prospective randomized controlled study45. 
From a logistical perspective, EPIC may be favored in those patients with unexpected peritoneal 
metastases who have not signed an informed consent for HIPEC so that they can be treated with 
full consent in the early postoperative period. It is possible that a single dose of  intraoperative 
chemotherapy (HIPEC) is not as effective as the 5-day intraperitoneal lavage used postoperatively 
(EPIC). However, EPIC has been shown to be associated with a higher incidence of  adverse 
events but not with a higher incidence of  mortality46. 
1.6. Objectives  
In relation to the promising results of  the first trials launched in the use of  prophylactic HIPEC 
in patients with colorectal cancer at high risk to peritoneal recurrence as well as the consolidated 
experience in the use of  the method that has reduced its morbidity within acceptable limits, we 
decided to propose in our Center for High Volume Oncology in the Treatment of  Colorectal 
Cancer, a single-center prospective controlled longitudinal cohort study in a consecutive series of  
patients eligible for surgery followed by intra-perioperative HIPEC comparing the results to a 
cohort of  patients undergoing chemotherapy standard adjuvant after surgery.  
The aims of  this thesis can be divided into three subsequent steps:  
- to evaluate the efficacy and safety of  HIPEC during surgery considering the reduction of  
local recurrence and peritoneal carcinosis compared with standard systemic adjuvant 
chemotherapy alone. The secondary end-points are the Overall Survival Rate (% OS) and 
the Disease Free Survival Rate (% DFS) at 6, 12, 18 and 24 months;  




open and laparoscopic adjuvant HIPEC; 
- cost-benefit analysis of  the adjuvant HIPEC method compared to traditional 
postoperative systemic chemotherapy alone, operating time, average length of  hospital 










CHAPTER   2 
 
Materials and Methods  
 
2.1. Study design 
his study is a mono-institutional, prospective, parallel, two-stage phase II trial. After the 
approval by the local Ethics Committee of  Palermo University (n°10/18 – 
14/11/2018), this study was carried out according to the Declaration of  Helsinki.  All 
participants included in the study signed a specific informed consent. 
Patients with advanced colon cancer or intraperitoneal rectosigmoid cancer (15 cm from the anal 
verge) with clinical T3/T4 N0-2 M0 stage or perforated colon cancer were prospectively enrolled 
between January 2019 and December 2020.  
Eligibility criteria also included:  
- histologically proven adenocarcinoma, cancer with mucinous (MC) or signet ring cell 
components (SRC); 
- age between 18 and 78 years that could undergo major surgery;  
- satisfactory cardiopulmonary function with no evidence of  myocardial infarction during 
the previous 6 months; 
- ECOG performance status of  0-2; 
- normal liver function; 
- normal renal function (blood urea < 50 mg/dl and creatinine level < 1.5mg/dl); 
- normal white blood cell count (>4000) and platelets (>150.000);  
- no major uncontrolled metabolic, cardiovascular or neurologic diseases; 
- minimal synchronous PC (nodules < 1 cm in the omentum and close to the primary 
tumor); 





PC and ovarian tumor deposits must have been macroscopically wholly resected at the same time 
as the primary tumor. The exclusion criteria were the following:  
- age under 18 years old or over 78; 
- the presence of  irresectable metastatic disease; 
- previous treatment for cancer; 
- the presence of  a second malignant tumor at high risk for recurrence; 
- Karnofsky performance status <50%; 
- extensive PC; 
- psycosis, drug or alcohol addiction; 
- active infection or severe associated medical conditions;  
- the presence of  diffuse peritonitis; 
- pregnancy. 
MC was diagnosed when >50% of  the tumor comprised a mucinous pattern on histological 
examination and secreting acini produced extracellular mucin in large amounts.  
2.2. Clinical outcomes evaluation 
The study endpoints of  the first-stage were length of  hospital stay, surgical and medical 
treatment-related toxicity after adjuvant HIPEC.  
Safety was reported according to the Dindo et al. classification for surgically related complications 
and to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0 for 
chemotherapy-related adverse events47,48. The surgical complication observation period included 
30 days after the surgical procedure. Surgical complications and adverse events occurring within 
30 postoperative days or during the same hospital stay were graded from zero to five. Follow-up 
assessment took place every three months during the first year and every six months later by 
physical examination, hematological and biochemical examinations, tumor markers (CEA, Ca 
19.9), thoracic/abdominal C.T. scan, colonoscopy was performed once a year after the first year 
of  follow-up or as needed according to oncologists’ evaluation.  
2.3. Treatments 
The selection process was divided into two steps. Preoperatively, potential candidates were 




colonoscopy; thoracic, abdominal and pelvic computed tomography (CT) scan with venous and 
oral contrast medium and serum markers (carcinoembryonic antigen, CA19.9). The second step 
consisted of  surgical exploration, with intraoperative pathological confirmation of  risk factors 
for PC. Samples for peritoneal cytology were taken after abdominal exploration. Colon resection 
was done according to the oncological principles of  adequate lymphadenectomy; total mesorectal 
excision was required for tumor of  the middle and lower rectum; tumor deposits on visceral and 
parietal surfaces were surgically removed and organ resections as surgically needed. Intraoperative 
pathologic evaluation assessed tumor depth and the histologic feature was mandatory to include 
patients in the study. In the HIPEC group at the end of  the surgery, patients who had signed 
informed consent and acceptance of  receiving intraperitoneal chemotherapy received HIPEC. 
Only in one patient we performed an early post-operative intraperitoneal chemotherapy (EPIC) 
to wait for a definitive pathology. EPIC wasn’t performed because we share the phenomenon of  
residual cancer cells which being encapsulated with fibrin probably make these cells less 
accessible for chemotherapy in an interval of  time longer than two weeks after surgery.  
HIPEC 
The chemotherapy solution is prepared in the pharmacy department and it is sent to the 
operating room in a closed light-protected bag with appropriate labeling which is handled with 
double gloves and the integrity of  the bag is checked. If  the bag is approved there is no risk of  
direct exposure and it is given to the person responsible for the perfusion, who must check the 
patient’s name, drug and dose delivered against those prescribed. 
There are two methods for intraperitoneal administration of  hyperthermic chemotherapy: open 
abdomen technique and closed abdomen technique. 
The open method is usually performed by the “Colosseum technique”, as described by 
Sugarbaker. In our center we use the closed technique.  
Peritoneal perfusion involves the use of  a machine that has the following characteristics (figure 
2): 
- a pump system 
- a thermostat or heat exchanger 
- integrated systems for temperature, pressure and flow control 
- data analysis system using a specific computerized program with real-time display of  the 




- an extracorporeal circuit (CEC). 
The equipment must be guaranteed by CE regulations. A series of  thermometers are also used 
for the constant evaluation of  intra-abdominal temperature. 
At the end of  the surgery, the tubes for the treatment of  chemo-hyperthermia, the drains and the 
thermal probes (for detecting the temperatures of  the perfusion liquid entering and leaving the 
abdomen) are placed through the abdominal wall. Generally, 4 polyphenestrated tubes are 
planted, which allow the chemotherapy solution to be introduced and extracted from the cavity at 
the same time and are positioned in the following ways: 
- tube n. 1 introduced below the right costal arch and positioned under the diaphragm and 
above the upper edge of  the liver        
- tube n. 2 introduced in the right hypochondrium and positioned in correspondence with 
the mesenteric root in the epigastrium        
- tube n. 3 at the level of  the right iliac fossa above pelvis        
- tube n. 4 below the left costal arch and positioned in the left subdiaphragmatic 
region.        
Tube n. 2 and n. 3 (in flow) are connected to Y fittings and therefore to the pump of  the chemo-
hyperthermia machine and will act as an infusion; the others (out flow) will be perfusate recovery 
drainages. The catheters used for HIPEC are left in place and will serve as drainages for the post-
operative course. In some cases, a Jackson-Pratt type drain is added to be maintained 
postoperatively longer than the drains used for the perfusate. When the closed abdomen 
technique is adopted, anastomoses and stomoses are usually performed before the laparotomy is 
closed; therefore, the suture of  the wall and the packaging of  the stoma must be perfectly sealed 
in order to avoid leakage of  chemotherapy solution during HIPEC. The abdominal wall is closed 
and the cavity is firstly washed with peritoneal dialysis solution in order to keep the catheters for 
drug administration and abdominal drainage clean of  any blood clots and tissue 
residues. Subsequently, after verifying that everything is proceeding regularly (conditions of  the 
patient, parameters of  the equipment, etc ...), the patient is covered with a cloth and the chemo 
hyperthermia cycle begins. The suturing of  the abdominal wall and the total coverage of  the 
affected area with a surgical cloth prevent the diffusion into the environment of  any aerosol 
produced during the chemotherapy treatment (nebulization). This treatment lasts about 30-60 
minutes depending on the neoplasm and during all this time a clinical perfusion scientist is 




completely aspirated in the abdomen and before reopening the abdominal cavity, a further 
washing is carried out by recirculating with the Performer LRT about 2 liters of  peritoneal 
dialysis solution for five minutes. According to the patient's BMI, the perfusion circuit is 
established using either a 5% glucose solution of  2 liters / m2 or physiological solution or 
according to the Sugarbaker’s protocol 1.5% dextrose peritoneal dialysis solution; the choice of  
solutions does not change the final result, but derives exclusively from the protocols adopted, 
containing the chemotherapy at the pre-established dose. Flow rates are adjusted to maintain 
stable temperatures with inflow temperatures not exceeding 42.5 ° C and efflux temperatures not 
exceeding 41 ° C. The patient's body temperature should not exceed 39.5 ° C using passive (turn 
off  routine warming devices) and active (cooled operating table and cold intravenous and 
intravescical fluids) methods of  cooling when needed. The intraperitoneal temperature is 
maintained at 41.5 ° C and monitored by thermometers inserted in the subphrenic space and in 
the pelvic cavity. The use of  the Swan-Ganz catheter in place during HIPEC to monitor 
cardiovascular function is discretionary; currently the use of  the "Vigileo ®" allows patient 
monitoring that can be superimposed on the Swan-Ganz catheter with less risk. The stability of  
the temperature is directly proportional to the flow of  the perfusate which must be maintained 
between 800 and 1200 mml / min. At the end of  the perfusion, of  variable duration depending 
on the drugs and protocols used, the liquid in the abdomen is completely aspirated and the inside 
of  the peritoneal cavity is washed with 2-3 liters of  Lactated Ringer's solution. In the immediate 
postoperative period, washing with a 1.5% dextrose solution is carried out in order to remove 
fibrin, cells in post-chemotherapy apoptosis and blood residues. The purpose of  these washes is 
to avoid that neoplastic cells not in apoptosis, therefore vital, are harnessed by fibrin and can 
result in what Sugarbaker calls "the cathedrals of  cancer", which could over time result in the 
recovery of  the disease. The postoperative abdominal wash technique is based on three stages: 
1. clamp closure of  all abdominal drains except the used one as in flow during perfusion.  
2. rapid infusion of  1000 cc of  solution from the inflow drain  
3. reopening of  all drains 
The postoperative washes are carried out every hour until a clear liquid is obtained or meat 
washes during the outflow, then continue every 2 hours for the first 12 hours after surgery. 
HIPEC is delivered with the closed technique with oxaliplatin at the dose of  460 mg/m2 in 2 
l/m2 of  dextrose solution over 30 minutes at a flow rate of  2 L/min and a temperature of  43°C. 
Before the HIPEC procedure and during surgery, patients received intravenous fluorouracil of  




Laparoscopic adjuvant HIPEC 
Minimally invasive access to the abdominal cavity is obtained, followed by adhesiolysis if  
indicated and thorough inspection of  the peritoneal surfaces. At least one multiperforated inflow 
catheter is placed through a 10–12 mm port in Douglas pouch and one multiperforated outflow 
catheter in the right subphrenic space. The patient’s body temperature will be monitored in the 
oesophagus. All trocars are tightly fixed to the skin to avoid fluid leakage during the procedure. 
After a total perfusion time of  30 min, the peritoneal fluid is totally suctioned and the abdomen 
is examined for evidence of  tissue injury or bleeding. A suction drain will be left in Douglas 
pouch for 24 h. The other port sites are closed in a standard fashion (figure 3). Postoperative 
care after simultaneous HIPEC will be according to the primary colonic resection following an 
enhanced recovery program. After staged laparoscopic HIPEC, patients are fully mobilized at day 
one with normal diet and will intentionally be discharged from the first to the third day if  the 
institutional discharge criteria are fulfilled. Hematologic parameters will be determined at day 14, 
followed by start of  systemic chemotherapy. 
Open adjuvant HIPEC 
Open adjuvant HIPEC can be performed simultaneously in patients undergoing primary open 
resection and staged open adjuvant HIPEC can be performed by re-laparotomy in patients who 
underwent primary open CRC resection. Besides the access to the peritoneal cavity, the 
procedure is similar to the laparoscopic approach as described above. Preferably, a closed 
perfusion is performed rather than a Colosseum technique to have similar pharmacokinetics as a 
laparoscopic approach. After positioning of  the in- and outflow catheters, the abdomen will be 
closed and subsequently perfusion will be started (figure 4). Postoperative care is similar to the 
laparoscopic approach with an anticipated day of  discharge between day two to five if  discharge 
criteria are fulfilled. Hematologic parameters will be determined at day 14, followed by start of  
systemic chemotherapy. 
All the specimens were histopathologically examined. Details about T, N, TNM stage, degree of  
differentiation and circumferential margins of  resection were recorded. 
Adjuvant s-CT was administered within 6–8 weeks after surgery, if  indicated by medical 
oncologists, according to international guidelines. During postoperative follow-up, physical 
examination, thoracic/abdominal CT scan and oncological marker measurements were 
performed every three months during the first 2 years and every six months thereafter. 




operated by the same two surgeons in the same period.  
2.4. Statistics 
The size of  this study (two independent samples) was calculated employing a probability of  a 
type-1 error 10% cutoff  (alpha 0.1), and a probability of  a type-2 error related to the study power 
(power 1-b) cutoff  of  20% cutoff  (beta 0.80)49. The endpoints were binomial, therefore for an 
anticipated mean of  3.5 + 1.5 in the control group and an assumed 35% increase in complication 
rate in the experimental arm with an enrollment ratio of  2:1, a total of  49 evaluable patients had 
to be enrolled, at least 18 and 31 in the experimental group and the control one respectively. 
Continuous monitoring for toxicity using a Pocock-type boundary was employed with an event 
probability (θ) of  0.2 and the desired probability of  early stopping of  0.0550. The trial will be 
stopped if  the number of  dose-limiting toxicities is equal to or exceeds bn out of  n patients with 
completed follow-up. This boundary is equivalent to testing the null hypothesis; after each 
patient, the event rate is equal to 0.1, using a one-sided level 0.026846 test. Sequential boundaries 
were used to monitor the dose-limiting toxicity rate. The accrual will be halted if  excessive 
numbers of  dose-limiting toxicities were seen: if  the number of  dose-limiting toxicities is equal 
to or exceeds bn out of  n patients with full follow-up. As shown in table2, this is a Pocock-type 
stopping boundary that yields the probability of  crossing the boundary at most [probability of  
early stopping] when the dose-limiting toxicity rate is equal to the acceptable rate [event 
probability θ]. 
A descriptive analysis of  all included patients was performed. Patient characteristics, tumor 
characteristics, and operative findings by lymphadenectomy or other surgical maneuvers were 
compared using Wilcoxon’s test for quantitative variables and chi-square or Fisher’s exact tests for 
qualitative variables. The time-dependent comparison was constructed using the Kaplan–Meier 






CHAPTER   3 
Results  
 
3.1 Patient population 
verall, 49 patients were enrolled in the study. Table 3 reports the main clinical and 
demographic characteristics of  the enrolled patients.  Eighteen patients were candidate to 
receive post-surgery HIPEC and 31 patients had surgery only. Fourteen out of  the eighteen 
patients who were candidates for HIPEC were evaluable (83%). Three patients did not reach 
intraoperatively criteria to receive post-surgery HIPEC.  Other patients didn’t accept the study, some 
hadn’t normal white blood cell count, in one case a perforation of  diaphrammatic peritoneal didn’t permit 
the HIPEC. Table 3 reports no statistically significant differences between the two groups of  patients in 
terms of  gender, median age, the primary tumor site, percentage of  patients treated with neoadjuvant 
chemotherapy or radiotherapy. Nearly one-third of  patients had the primary tumor in the ascending 
colon/hepatic flexure, while the remaining ones had it in the descending colon/splenic flexure or sigmoid 
colon. Three patients had neoadjuvant chemotherapy and only one pre-operative radiotherapy. Video-
laparoscopic surgery was done in 33% and 39% of  HIPEC and control groups, respectively. In some 
patients, it was necessary to combine the resection of  other organs with the standard colectomy. 
Peritoneal washing was cytologically negative in all cases.  
HIPEC group: they were 9 women and 5 men, with an average age of  61 (38-76 years). A right 
hemicolectomy was performed in 5 patients (3 performed in videolaparoscopy and in one case associated 
with cholecystectomy); 3 patients underwent anterior resection of  the rectum with ileostomy packaging; 3 
patients with anterior resection of  the rectum en bloc with uterus and adnexa; in 1 patient an extended 
multivisceral resection was performed in addition to the transverse colon and the left colon, the spleen, 
the pancreas body-tail, the gastric body-antrum, the left kidney and adrenal gland; in 1 patient left 
hemicolectomy was extended to the transverse colon; 1 patient underwent en bloc anterior rectal resection 
with cystectomy and prostatectomy.  
Control group: it includes 31 patients, 17 men and 14 women, with an average age of  62, who were referred 





All the surgical procedures met the oncological radicality criteria and were R0. Definitive histological 
examinations confirmed the pT3-T4 pN0-N2 stage (figures 5, 6, 7, 8, 9). No complications were 
recorded in the postoperative course and the average hospital stay was approximately one week. The 
absence of  complications was recorded in the perioperative up to 30 days. 
Patients were referred to adjuvant therapy with XELOX regimen, capecitabine or follow-up alone. 
The follow-up controls, carried out up to now according to the protocols of  the international guidelines, 
have all been negative. 
The pandemic coronavirus disease 2019 (COVID-19) has reduced the possibility to enroll patients.  
3.2 Outcomes 
Table 4 shows results in terms of  duration of  surgical procedure subtracting time dedicated to hyper-
thermic intraperitoneal chemotherapy procedure, length of  hospitalization, surgical complications, side-
effects related to chemotherapy and impact of  HIPEC on post-surgical chemotherapy. No significant 
difference was seen in median time spent in the hospital (figure 10) with a median stay of  7 days in both 
groups (Gehan-Breslow-Wilcoxon test p=0.5720, N.S.; Mantel-Haenszel HR 0,0922, 9%% CI 0.4282-
2.299). As shown in figure 11, the surgical procedure’s median duration was longer in the HIPEC group 
than in the control one (median 192 versus 138 minutes). This difference was statistically significant when 
the log-rank test was applied (p=0.0037), but not with the Gehan-Breslow-Wilcoxon test (p=0,0810).  The 
rate of  surgical complications as well side-effects potentially related to chemotherapy were equally 
distributed in both groups. Side-effects and surgical complications did not cross at any time the Pocock-
type boundary for side/effect monitoring (p=0.80, N.S.). Moreover, HIPEC did not affect subsequent 
adjuvant chemotherapy safety being toxicity the same in both groups of  patients. 
None of  the patients in the HIPEC group developed recurrence; one patient who had no indication for 
adjuvant CT during follow-up underwent chest CT showing suspected mediastinal lymphadenopathy with 
uptake on station 4R lymph nodes at the next PET scan. She was then subjected to c-EBUS-TBNA with 
histological diagnosis of  tumor-free lymph nodes. 
To date, the outcome records a 51-year-old patient in massive hepatic metastatic progression and death 
from cachexia approximately 6 months after surgery and a patient who died of  respiratory failure two 
months after surgery. 
In the remnant patients OS and DFR are 100%. 
In the control group four patients showed relapse of  disease: one developed pulmonary metastases 4 
months after the primary surgery and underwent left basal trisegmentectomy in VTS; one developed 




metastases after 3 months RFTA treatment and one had parietal peritoneal recurrence treated with 





CHAPTER   4 
Discussion 
 
etween 2010 and 2020 in our center “La Maddalena” were performed about1000 cases of  
colorectal resection for oncological pathology. In the same decade, the center developed a 
consolidated experience for various abdominal oncological diseases for which an indication 
for cytoreductive treatment with HIPEC (carcinosis from ovarian cancer, gastric cancer, etc 
...) is recommended. The overall complication assessment, according to DINDO et al. 
classification, recorded 0.05% of  mortality (class V). All interventions were performed only by two 
surgeons with advanced background and expertise in open and laparoscopic surgery. Postoperative 
colorectal staging recorded approximately 700 cases of  pT3 / pT4 pN0-2 (70%). Of  this population, to 
our knowledge, about 15% developed peritoneal carcinosis despite R0 resection and adjuvant treatment, in 
line with literature data. Metastatic diffusion into the peritoneal surface carries out a very unfavorable 
prognosis and a dismal quality of  life in many patients with recurrent/metastatic CRC51. CRS plus HIPEC 
has become a valid treatment option for colorectal PC. A 5-years overall survival (OS) rate of  35-40% has 
been reported for patients treated by CRS + HIPEC. This strategy is supported by a strong rationale: first, 
CRS combined with HIPEC improve CRC-PC survival, but most patients are not suitable for this 
demanding treatment due to extensive peritoneal involvement, systemic metastases and/or poor clinical 
conditions; second, CRS/HIPEC is maximally effective and safe when small-volume disease is treated; 
third, in the palliative setting, modern systemic chemotherapy (s-CT) and target agents appear to be less 
effective for peritoneal metastatic CRC than non-peritoneal metastatic CRC; finally, the absence of  
symptoms, as well as current limitations of  imaging, hamper early diagnosis and treatment52. Because of  
these aforementioned difficulties, for those patients with colo-rectal cancer at high risk for peritoneal 
carcinosis, although the characterization of  their genetic and epigenetic alterations may improve the 
prognostic model and allow a tailored therapy, difficult to apply in daily surgical practice, it seems justified 
a “proactive” surgical approach. The use of  adjuvant HIPEC has been tested at different time-points, 
either simultaneously with primary surgery, at the time of  second-look surgery after adjuvant systemic 





Researchers at the National Cancer Centre in Singapore have recently published an updated 
review of  the state of  the art of  surgical management plus HIPEC for locally advanced CRC53. 
The multicenter COLOPEC study was carried out in nine hospitals in the Netherlands and the 
primary endpoint was peritoneal metastasis free-survival at 18 months, according to an intention-
to-treat54. This study followed a pilot study, which reported a clear advantage for adjuvant delayed 
laparoscopic HIPEC after a median follow-up of  4.5 years in patients with a high risk of  
peritoneal spread55. In the COLOPEC trial, 204 patients with clinical or pathological T4, N0–2, 
M0 stage or perforated CRC were randomized before surgery in a 1:1 ratio to receive adjuvant 
systemic chemotherapy alone or HIPEC within 5-8 weeks after primary resection followed by 
standard adjuvant systemic chemotherapy54. Patients were stratified for perforation, stage of  the 
disease, age (<65 years or ≥65 years), and surgical approach (open or laparoscopic). Adjuvant 
HIPEC consisted of  systemic leucovorin potentiated fluorouracil followed by intraperitoneal 
hyperthermic delivery of  oxaliplatin by either laparoscopic or open procedure to allow 
exploration of  the abdominal cavity for peritoneal staging and adhesiolysis when necessary. This 
technical approach was based on the assumption that second-look surgery, first described more 
than five decades ago, remains the only method to ascertain the presence of  minimal progression 
at the peritoneal surface55. This study showed no statistically significant difference being 
peritoneal metastasis-free survival at 18-months 80.9% for the HIPEC group versus 76.2% for 
the control group, respectively. The main criticism is the high proportion (91%) of  patients who 
received delayed adjuvant HIPEC 5 to 8 weeks after primary tumor resection when adhesions 
and tumor cell entrapment may have limited the drug distribution and effectiveness of  HIPEC. 
Moreover, 9% of  the 100 patients in the HIPEC group had peritoneal invasion before delivering 
HIPEC.  
Another recently published prospective open-label, phase III trial PROPHYLOCHIP, carried out 
in France, failed to improve disease-free survival compared to standard surveillance56. This trial 
enrolled 150 patients affected by CRC who underwent resection of  the primary tumor and 
synchronous peritoneal or ovarian metastases and treated with adjuvant systemic chemotherapy. 
Patients were randomized to no further therapy or second-look surgery at the end of  
chemotherapy, plus, if  no recurrence, oxaliplatin- or mitomycin-based HIPEC. The study did not 
reach the primary endpoint being 3-year disease-free survival 53% (95% CI 41-64) in the 




CI 0·61-1·56). These results disfavored the use of  second-look surgery plus HIPEC in this 
clinical setting. 
Overall, the results of  these two-phase III trials challenged the effectiveness of  HIPEC protocol 
with oxaliplatin and raised the question of  whether delayed and limited exposure to 
chemotherapy (only 30 minutes) may negatively affect its antitumor effect. Timing of  adjuvant 
HIPEC is another point of  debate since it should be ideally delivered during primary surgical 
resection to avoid tumor cell entrapment and delayed microscopic disease management. Statistical 
sample underpowering could be another explanation for the failure to reach study endpoints.   
Although surgery plus HIPEC yielded unsatisfactory results in patients with a high PCI score, it 
showed promising results in patients at high risk of  recurrence, but still without clinically evident 
peritoneal spread. Generally, CRC patients with a low PCI score show better survival rates and 
lower postoperative morbidity after treatment with surgery and HIPEC57. Therefore, the 
recognition and management of  peritoneal invasion as early as possible may play a pivotal role in 
maximizing therapeutic results and, ultimately, in patients’ survival and quality of  life54. Unluckily 
early detection of  peritoneal invasion is a significant challenge due to the lack of  signs and 
symptoms and the relatively low accuracy of  imaging techniques. CT scan may detect only less 
than 30% of  peritoneal deposits with a size <5 mm58,59. Recently diffusion-weighted magnetic 
resonance (DW-MR) has been introduced as a possible imaging method60. 
To date there are two Italian prospective case-control studies to evaluate the feasibility and utility 
of  HIPEC in reducing PC in high-risk CRC patients: the procedures were performed with 
oxalipatin-based HIPEC and mitomycin plus cisplatin-based HIPEC respectively; in both HIPEC 
was given at the same time as primary surgery. In the study by Sammartino et al.46 high-risk cases 
were defined by T3/T4, perforation and mucinous histology. The experimental group underwent 
carcinosis prevention strategies including complete omentectomy, bilateral salpingo-
oophorectomy, hepatic round ligament resection and appendectomy. After 48 months, PC and 
local recurrence developed significantly less often in the patients who had received prophylactic 
HIPEC compared to the control group (4% vs. 28%) (P<0.03). Patients in the prophylactic 
HIPEC group also survived longer (median overall survival 59.5 vs. 52 months). Despite similar 
morbidity, Kaplan-Meier survival curves disclosed significantly longer disease-free and overall 




In the paper by Baratti et al.61, high-risk cases were defined as T4, synchronous krukemburg 
tumours and minimal peritoneal disease. Prophylactic HIPEC was with cisplatin and mitomycin-
C and correlated to lower PC cumulative incidence [hazard ratio (HR) 0.04, 95% CI, 0.01–0.31; 
P=0.002] and better overall survival (HR 0.25, 95% CI, 0.07–0.89; P=0.039) and progression-free 
survival (HR 0.31, 95% CI, 0.11–0.85; P=0.028). Reported morbidities from HIPEC were 
minimal in both papers and there were no reported mortalities. The preliminary results have also 
shown that prophylactic HIPEC is feasible with minimal morbidity and does not delay time to 
adjuvant systemic therapy.  
In our study, we report the feasibility and safety of  colorectal surgery plus HIPEC in terms of  
length of  hospital stay, surgical and medical treatment-related toxicity in a mono-institutional 
series of  CRC patients high risk of  recurrence, but still without evident signs of  peritoneal 
spread who underwent radical surgery. As Sammartino et al. did, we chose to include pT3 tumor 
according to the study of  Kojima62 who assessed that when a pT3 tumor invades the elastic 
lamina, as it does in almost 40% of  patients, the clinical outcome almost always matches with 
those patients with pT4 cancer. With regard to histology of  the tumor, several clinical and post-
mortem studies have already suggested that colo-rectal mucinous adenocarcinoma seems to 
metastasize more frequently to the peritoneum compared with other types of  adenocarcinoma. 
Although the detailed mechanisms of  peritoneal metastasis from mucinous colorectal 
adenocarcinoma are not clear, the production of  mucus under pressure might allow cancer cells 
to separate tissue planes in the bowel wall and more frequently gain access to the peritoneal 
cavity. In our hands, colorectal surgery plus HIPEC was feasible without an increase in surgical- 
or chemotherapy-related complications. The median length of  hospital stay was not statistically 
different in patients who received HIPEC and those who did not. 
Time spent on the surgical procedure was slightly longer in the HIPEC group than in the control 
one. This difference reached statistical significance. Even though other authors reported a 14% 
rate of  postoperative complications after adjuvant HIPEC54, in our experience, both surgical 
complications and chemotherapy-related toxicity were low. None of  the 14 patients showed 
peritoneal recurrence or distant metastases after a median follow-up of  12 months. Although the 
patients sample size is too small to draw conclusions about survival outcomes, also due to the 
pandemic COVID-19 situation, our results are, however, in line with the encouraging results of  




support the need for a proper patient selection based on clinical criteria if  surgeons plan to 
deliver HIPEC simultaneously with primary or staged resection and if  prophylactic resection of  
target organs may influence outcomes. These criteria include data from pre-operative imaging, 
histological biopsies, biomarkers and intra-operative findings. However, in our experience, it was 
difficult to select patients based on clinical staging adequately. A well-defined cT4 stage based on 
imaging or intraoperative findings frequently turns out to have a pathological T3 stage. Therefore, 
this proactive management of  patients with stage T4, as the only risk factor, could represent an 
overtreatment as recently suggested63. In our HIPEC series only two patients were classified as 
adenocarcinoma pT3 pN0 and we motivated this possible “over- treatment” with their young age. 
To eliminate the doubt of  Sammartino et al.64 who cannot state whether the good results in terms 
of  peritoneal recurrence and DFS in the HIPEC group depend on the associated surgical 
procedure, we didn’t perform the resection of  the target organs because we hypothesized that 
potential micro-metastases at these sites are sufficiently treated with HIPEC. Three trials, the 
Italian PROMENADE, the Chinese APEC and the Spanish HIPECT4 are currently investigating 
the early use of  adjuvant HIPEC for locally advanced CRC65-67. 
Conclusions 
“It’s what the surgeon doesn’t see that kills the patient” said Sugarbaker68. It was this sentence that 
prompted us to undertake this research project. In our experience colorectal surgery plus HIPEC 
treatment is safe and feasible, it seems to be a promising strategy for patients with advanced 
colorectal cancer to prevent the development of  peritoneal recurrence and improve prognosis of  
this group of  patients. The goal is to avoid peritoneal disease or to treat it at its earliest stages 
when citoreduction and HIPEC have the biggest impact. Our data concerning the impact of  
survival parameters are not available due to follow-up shortness. Further studies are needed to 
better identify early peritoneal invasion and optimize the role of  colorectal surgery plus HIPEC 
in patients at high risk of  peritoneal cancer spread. It is necessary not to stop at the appearance, 






CHAPTER   5 
Tables & Figures  
 
 
Figure 1. The peritoneal metastatic cascade 
Pathophysiology of  colorectal peritoneal carcinomatosis: the peritoneal metastatic cascade. The emergence 
of  PC is the result of  molecular crosstalk between tumor cells and host elements, comprising several well-defined 
steps. A: Individual or clumps of  tumor cells detach from the primary tumor and gain access to the peritoneal cavity. 
Spontaneous exfoliation of  tumor cells from the primary tumor can be promoted by the down-regulation of  E-
cadherin, increased interstitial fluid pressure, and iatrogenically during surgery; B: The free tumor cells become 
susceptible to the regular peritoneal transport. Peritoneal transport is due to changes in the intra-abdominal pressure 
during respiration, gravity and peristalsis of  the bowel; which results in a clockwise flow from the pelvis, along the 
right paracolic gutter and to the subdiaphragmatic space and finally towards the pelvis again; C: Attachment of  
tumor cells to distant peritoneum occurs via two processes, denominated transmesothelial and translymphatic 
metastasis. During transmesothelial metastasis, loose tumor cells directly adhere to distant mesothelium through 
adhesion molecules. During translymphatic metastasis, free tumor cells gain access to the submesothelial lymphatics 
through lymphatic stomata. Preferential tumor growth in the milky spots of  the greater omentum has been 
observed; D: Tumor cells invade the submesothelium. In areas of  absent or rounded (cuboidal) mesothelial cells, 
tumor cells interact with the laminar network of  the basement membrane through integrin-mediated adhesion. 
Subsequent invasion of  the submesothelial tissue occurs via degradation by proteases (MMPs); E: Systemic 













































Figure 5 - Case 2. Pre-operative imaging TC, intra-operative macroscopic imaging of  surgical specimen and 










Figure 6 – Case 4. Pre-operative imaging TC and macroscopic imaging of  surgical specimen of  a case of  colon 
cancer which required extended multivisceral resection to the transverse colon and the left colon, the spleen, the 
pancreas body-tail, the gastric body-antrum, the left kidney and adrenal gland required the resection of  spleen, 









































Figure 8 – Case 15. A case of  miss-match between a well-defined cT4 stage based on imaging or 
intraoperative findings that turns out to have a pathological T3 stage. The surgical procedure included, in addition 
to colonic resection, cystectomy, prostatectomy and ureterocutaneostomy and Bricker urinary diversion. HIPEC 
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Table 1 Clinical and intraoperative histopathologic features of  the primary cancer as an estimate of  the incidence 
of  subsequent local recurrence and/or peritoneal metastases to guide proactive treatment with perioperative 
chemotherapy at the time of  primary colorectal resection. 
 
 
Number of patients n 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Boundary bn - - 3 4 4 4 5 5 5 6 6 6 7 7 









  HIPEC CONTROLS  
N. of patients  18 (100%) 31 (100%)  
N. evaluable patients  15 (83%) 31 (100%)  
Age (years)  Median (range) 58 (46-76) 60 (44-78)  
Gender Male 5 (36%) 17 (55%) p=0.275787 
Female  9 (64%) 14 (45%) 
Site of primary ascending colon* 6 (33%) 8 (26%) p=NS 
transverse colon 0 1 (03%) 
descending colon** 3 (17%) 10 (32%) 
sigmoid/rectal colon 9 (50%) 12 (39%) 
CEA at basal > 4  2 (11%)   
Neoadjuvant CT   Yes 1 (6%) 1 (3%)  
FOLFOX 1 0 
XELOX 1 0 
Capecitabine 0 1 
None 13 30 
Neoadjuvant R.T.  0 1 
Surgery  Open 12 (67%) 19 (61%) p=0.059126 
NS VLS 6 (33%) 12 (39%) 
hemicolectomy  10 17 p=NS 
rectal anterior resection 8 14 
Ileostomy 6 5 
Other organs resect-
ed 
Pancreas 1 0  
gall bladder 1 0 
uterus/ovary 3 3 
urinary bladder 2 2 
Peritoneum 1 3 
Prostate 1 0 
Peritoneal washing Negative  14 31 




Histology Adenocarcinoma 18 (100%) 31 (100%)  
Post-surgical stage  pT3, N0, M0 5 2  
pT3, N1a, M0 1 6 
pT3, N1b, M0  1 11 
pT3, N2a, M0 2 3 
pT3, N2b, M0 2 3 
pT3, N1c, M0 0 1 
pT3, N2b, M0 0 1 
pT3, N0,M1 (per) 1 0 
pT4, N0, M0 0 1 
pT4a, N1b, M0 0 2 
pT4b, N0, M0 1 0 
pT4b, N1a, M0 0 1 
pT4, N2a, M0 1 0 
pT4b, N1b, M0 1 1 
pT4, N2b, M0 1 0 
*Including hepatic flexure; ** Including splenic flexure  














  HIPEC CONTROLS  
Duration of surgery 
(minutes) 







Nausea/vomiting 1 2 p=NS 
None 14 29 
Hospital stay (days) median (range) 7 (6-21) 7 (5-15) p=NS 
Complications after dis-
charge 
 1 § 1 ^  
Adjuvant chemotherapy  11(73%) 25(81%) p=NS 
FOLFOX 2 4 
XELOX  7 18 
CAPECITABINE 2 3 
none  4 (27%) 6 (19%) 
Percent of planned cycles  90%) 87 (%) p=NS 
Side-effects (> grade 3) Mucositis 2 (18%) 4 (16%) p=NS 
Diarrhea  2 (18%) 3 (12%) 




Platelets 0 1 
Delays in chemotherapy yes 4 (27%) 7 (28%) p=NS 
 no    
Adjuvant R.T.  1 1  
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